<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04877288</url>
  </required_header>
  <id_info>
    <org_study_id>IM103-402</org_study_id>
    <secondary_id>2018-000237-12</secondary_id>
    <nct_id>NCT04877288</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Benefits and Risks of Conversion of Existing Adolescent Kidney Transplant Recipients Aged 12 to &lt;18 Years to a Belatacept-based Immunosuppressive Regimen as Compared to Continuation of a Calcineurin Inhibitor-based Regimen, and Their Adherence to Immunosuppressive Medications</brief_title>
  <official_title>A Prospective, Open-label, Multicenter, Randomized Study to Evaluate the Benefits and Risks of Conversion of Existing Adolescent Renal Allograft Recipients Aged 12 to Less Than 18 Years of Age to a Belatacept-based Immunosuppressive Regimen as Compared to Continuation of a Calcineurin Inhibitor-based Regimen, and Their Adherence to Immunosuppressive Medications</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the benefits and risks of conversion of existing&#xD;
      adolescent kidney allograft recipients aged 12 to less than 18 years of age to a&#xD;
      belatacept-based immunosuppressive regimen as compared to continuation of a calcineurin&#xD;
      inhibitor-based regimen and their adherence to immunosuppressive medications.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 7, 2021</start_date>
  <completion_date type="Anticipated">December 2, 2027</completion_date>
  <primary_completion_date type="Anticipated">August 11, 2026</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of participants who survive with a functional graft with estimated glomerular filtration rate (eGFR) &gt; 30 mL/min/1.73 m2 (updated Schwartz formula) at 24 months post-randomization</measure>
    <time_frame>24 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Participant and graft survival: Proportion of participants who survive with a functioning graft</measure>
    <time_frame>6 and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participant and graft survival: Proportion of participants who survive</measure>
    <time_frame>6, 12, and 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participant and graft survival: Proportion of participants who experience death-censored graft loss</measure>
    <time_frame>6, 12, and 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute rejection: Incidence of clinically suspected biopsy-proven acute rejection (BPAR)</measure>
    <time_frame>3, 6, 12, and 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute rejection: Severity of clinically suspected, biopsy confirmed rejection as determined by locally and centrally reviewed histopathology</measure>
    <time_frame>3, 6, 12, and 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal function as assessed by: Serum creatinine concentration</measure>
    <time_frame>Up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal function as assessed by: Estimated GFR (eGFR per updated Schwartz combined equation)</measure>
    <time_frame>Up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal function as assessed by: eGFR per updated bedside Schwartz approximating equation</measure>
    <time_frame>Up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal function as assessed by: eGFR per Full Age Spectrum (FAS) equation of Potell et al</measure>
    <time_frame>Up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proteinuria, as assessed by urinary protein:creatinine ratio (UPCR), as determined from single-voided urine specimens</measure>
    <time_frame>Up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Slope of change in eGFR over time, as assessed by baseline-adjusted mean eGFR determinations at protocol-specified study visits</measure>
    <time_frame>Up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adherence to immunosuppressive medications as assessed by variation in calcineurin inhibitor pre-dose whole blood concentrations by summaries over time of monitored adherence to orally administered immunosuppressive medications</measure>
    <time_frame>up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adherence to immunosuppressive medications, as assessed by: Variations in pre-dose concentrations of calcineurin inhibitor in whole blood</measure>
    <time_frame>Up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adherence to immunosuppressive medications, as assessed by: 7-day recall of missed and late doses of each orally administered immuno-suppressive medication at protocol-specified study visits</measure>
    <time_frame>Up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adherence to immunosuppressive medications, as assessed by: Monitoring of compliance with monthly belatacept infusions</measure>
    <time_frame>Up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adherence to immunosuppressive medications, as assessed by: Periodic review of parents' and patients' perceived barriers to adherence to the prescribed immunosuppressive medications regimen</measure>
    <time_frame>Up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean blood pressure over time</measure>
    <time_frame>Up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean blood pressure changes from baseline over time</measure>
    <time_frame>Up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intensity of antihypertensive drug therapy, defined as the total number of medications used to maintain BP control</measure>
    <time_frame>Up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Monitoring of safety laboratory parameters over time: Mean fasting lipid profiles</measure>
    <time_frame>Up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Monitoring of safety laboratory parameters over time: Fasting blood glucose concentrations</measure>
    <time_frame>Up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Monitoring of safety laboratory parameters over time: Hemoglobin A1c concentrations</measure>
    <time_frame>Up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Donor Specific antibodies (DSA): Proportion of participants with pre-existing anti-human leukocyte antigen (HLA) DSAs at baseline and with de novo anti-HLA DSA post-randomization</measure>
    <time_frame>6, 12, and 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity of belatacept as determined by the proportion of participants with detectable serum anti-belatacept antibodies</measure>
    <time_frame>6, 12, and 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Belatacept pre-dose (C0) serum concentrations</measure>
    <time_frame>Up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean percent belatacept CD86 receptor occupancy</measure>
    <time_frame>Baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-randomization changes from baseline percent belatacept CD86 receptor occupancy</measure>
    <time_frame>6, 12, and 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability of belatacept following conversion: Incidence of Adverse Events (AEs)</measure>
    <time_frame>up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability of belatacept following conversion: Incidence of Serious Adverse Events (SAEs)</measure>
    <time_frame>Up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability of belatacept following conversion: Incidence of laboratory marked abnormalities</measure>
    <time_frame>Up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants within each stage of the Tanner staging scale</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>The Tanner scale is a measure of pubertal development (sexual maturation) in children and adolescents with components described for each sex, rated separately on a scale of stage one to stage five, with 1 for preadolescent and 5 for mature/adult</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Linear growth (height)</measure>
    <time_frame>Up to 24 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">102</enrollment>
  <condition>Renal Allograft Recipients</condition>
  <arm_group>
    <arm_group_label>Arm 1: Conversion from a CNI- to belatacept-based regimen after a period of overlap</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Conversion followed by tapering and discontinuation of the calcineurin inhibitor (CNI)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2: Continue calcineurin inhibitor-based regimen</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Belatacept</intervention_name>
    <description>Specified dose on specified days</description>
    <arm_group_label>Arm 1: Conversion from a CNI- to belatacept-based regimen after a period of overlap</arm_group_label>
    <other_name>Nulojix</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tacrolimus</intervention_name>
    <description>Specified dose on specified days</description>
    <arm_group_label>Arm 1: Conversion from a CNI- to belatacept-based regimen after a period of overlap</arm_group_label>
    <arm_group_label>Arm 2: Continue calcineurin inhibitor-based regimen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclosporine A</intervention_name>
    <description>Specified dose on specified days</description>
    <arm_group_label>Arm 1: Conversion from a CNI- to belatacept-based regimen after a period of overlap</arm_group_label>
    <arm_group_label>Arm 2: Continue calcineurin inhibitor-based regimen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mycophenolate Mofetil</intervention_name>
    <description>Specified dose on specified days</description>
    <arm_group_label>Arm 1: Conversion from a CNI- to belatacept-based regimen after a period of overlap</arm_group_label>
    <arm_group_label>Arm 2: Continue calcineurin inhibitor-based regimen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Enteric Coated Mycophenolate Sodium</intervention_name>
    <description>Specified dose on specified days</description>
    <arm_group_label>Arm 1: Conversion from a CNI- to belatacept-based regimen after a period of overlap</arm_group_label>
    <arm_group_label>Arm 2: Continue calcineurin inhibitor-based regimen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Corticosteroids</intervention_name>
    <description>Specified dose on Specified days</description>
    <arm_group_label>Arm 1: Conversion from a CNI- to belatacept-based regimen after a period of overlap</arm_group_label>
    <arm_group_label>Arm 2: Continue calcineurin inhibitor-based regimen</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        For more information regarding Bristol-Myers Squibb Clinical Trial participation, please&#xD;
        visit www.BMSStudyConnect.com&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  Male and female adolescents 12 to less than 18 years of age&#xD;
&#xD;
          -  Recipients of a renal allograft from a living or deceased donor transplanted at least&#xD;
             6 calendar months prior to enrollment&#xD;
&#xD;
          -  Receiving a stable regimen of a calcineurin inhibitor (CNI), with mycophenolate&#xD;
             mofetil (MMF) or enteric-coated mycophenolate sodium/mycophenolate mofetil&#xD;
             (EC-MPS/MPA), with or without daily corticosteroids for ≥1 calendar months prior to&#xD;
             randomization&#xD;
&#xD;
          -  Clinically stable renal function during the 12-week period prior to screening, in the&#xD;
             opinion of the investigator and based on protocol-defined criteria for proteinuria and&#xD;
             estimated glomerular filtration rate (eGFR)&#xD;
&#xD;
          -  Serologic evidence of past exposure to Epstein-Barr virus (EBV) and current absence of&#xD;
             EBV DNA replication at or prior to renal transplantation and during the Screening&#xD;
             period&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Recipients with EBV serostatus negative or unknown at screening or at transplant&#xD;
&#xD;
          -  Treatment for biopsy-proven acute rejection (BPAR) of any degree of severity within 6&#xD;
             calendar months prior to enrollment&#xD;
&#xD;
          -  Biopsy-confirmed antibody-mediated acute rejection at any time with the current&#xD;
             allograft&#xD;
&#xD;
          -  Banff 97 grade IIA or higher acute cellular rejection (or equivalent), or treatment&#xD;
             with plasmapheresis or rituximab for any acute rejection at any time with the current&#xD;
             allograft&#xD;
&#xD;
          -  Current evidence or past history of active or inadequately treated latent tuberculosis&#xD;
             (TB) infection&#xD;
&#xD;
          -  Previously treated with belatacept or previously enrolled in a belatacept trial with&#xD;
             their present allograft&#xD;
&#xD;
        Other inclusion/exclusion criteria apply&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Recruiting sites have contact information. Please contact the sites directly. If there is no contact information,</last_name>
    <phone>please email:</phone>
    <email>Clinical.Trials@bms.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>First line of the email MUST contain NCT # and Site #.</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Ghent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <contact>
      <last_name>Site 0047</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Bron</city>
        <zip>69500</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Site 0028</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Site 0027</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Site 0011</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Site 0026</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Köln</city>
        <zip>50937</zip>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Site 0010</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Milano</city>
        <zip>20122</zip>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Site 0030</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Torino</city>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Site 0036</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Amsterdam</city>
        <zip>1105 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <contact>
      <last_name>Site 0015</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Site 0001</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Rivas Vaciamadrid</city>
        <zip>28523</zip>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Site 0012</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Site 0003</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Manchester</city>
        <zip>M13 9WL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <contact>
      <last_name>Site 0008</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Nottingham</city>
        <zip>NG7 2UH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <contact>
      <last_name>Site 0009</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html</url>
    <description>BMS Clinical Trial Information</description>
  </link>
  <link>
    <url>https://www.bmsstudyconnect.com/s/US/English/USenHome</url>
    <description>BMS Clinical Trial Patient Recruiting</description>
  </link>
  <link>
    <url>https://www.fda.gov/Safety/MedWatch/SafetyInformation/default.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>May 3, 2021</study_first_submitted>
  <study_first_submitted_qc>May 6, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 7, 2021</study_first_posted>
  <last_update_submitted>May 6, 2021</last_update_submitted>
  <last_update_submitted_qc>May 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acute rejection</keyword>
  <keyword>Belatacept</keyword>
  <keyword>Calcineurin inhibitors (cyclosporine, tacrolimus)</keyword>
  <keyword>Conversion</keyword>
  <keyword>Donor-specific antibodies</keyword>
  <keyword>eGFR</keyword>
  <keyword>Immunosuppressive regimen</keyword>
  <keyword>Adolescent kidney transplant recipients</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Mycophenolic Acid</mesh_term>
    <mesh_term>Abatacept</mesh_term>
    <mesh_term>Tacrolimus</mesh_term>
    <mesh_term>Cyclosporins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

